Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Pinney

Sports Medicine Midland, MI Medical Doctor

NPI 1982617247 CMS profile 225103

4401 N Campus Ridge Dr, Suite C2000, Midland, MI 48640

Open in the dashboard

General payments

$67,032

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Pinney of Midland, MI is reported in the CMS Open Payments database as having received $67,032 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2024 General $62 2
2023 General $1,428 4
2022 General $25,668 42
2021 General $26,772 40
2020 General $1,512 3
2019 General $11,569 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Pinney
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jack Pinney were reported at $20. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Jack Pinney Sports Medicine median Middle half National median
2019 $11,569 $119 $35–$362 $163
2020 $1,512 $77 $24–$275 $114
2021 $26,772 $104 $28–$340 $132
2022 $25,668 $94 $31–$272 $149
2023 $1,428 $91 $34–$271 $160
2024 $62 $126 $38–$294 $164
2025 $20 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $47,669 73 payments
  2. Merck Sharp & Dohme Corporation $19,129 33 payments
  3. Ferring Pharmaceuticals Inc. $53 3 payments
  4. Flexion Therapeutics, Inc. $46 2 payments
  5. Zimmer Biomet Holdings, Inc. $45 1 payment
  6. DePuy Synthes Sales Inc. $32 1 payment
  7. Bioventus LLC $20 1 payment
  8. Djo, LLC $19 1 payment
  9. Pacira Pharmaceuticals Incorporated $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,250 26 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $26,876 32 payments
  3. Travel and Lodging $2,406 25 payments
  4. Food and Beverage $499 33 payments
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $27,027 43 payments
  2. Nexplanon Womens Health $20,642 30 payments
  3. NEXPLANON Womens Health $19,129 33 payments
  4. EUFLEXXA $53 3 payments
  5. Zilretta $46 2 payments
  6. Gel-One Cross-linked Hyaluronate $45 1 payment
  7. NA Trauma $32 1 payment
  8. NA Trauma $32 1 payment
  9. Hammerlock $32 1 payment
  10. GELSYN-3 $20 1 payment
  11. Other $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

828

Median for Sports Medicine: 144

Drug cost

$8,362

Median for Sports Medicine: $1,027

Branded share of claims

4.8%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 498 $1,922
Diclofenac Sodium Generic 22 $1,243
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 11 $923
Celecoxib Generic 52 $901
Rosuvastatin Calcium Generic 55 $864
Atorvastatin Calcium Generic 27 $446
Albuterol Sulfate Hfa Albuterol Sulfate Brand 13 $434
Pantoprazole Sodium Generic 18 $380
Montelukast Sodium Generic 13 $223
Amlodipine Besylate Generic 13 $183

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$44,125

Medicare's payments for the services billed

Medicare patients

215

Average age 72

Services billed

1,532

143 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 27%
Diabetes 24%
Ischemic heart disease 23%
Chronic kidney disease 21%
Osteoporosis 19%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record